$104.98 Million in Sales Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter

Analysts predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post $104.98 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Halozyme Therapeutics’ earnings. The lowest sales estimate is $93.70 million and the highest is $119.27 million. Halozyme Therapeutics posted sales of $65.32 million in the same quarter last year, which indicates a positive year-over-year growth rate of 60.7%. The business is expected to report its next earnings results on Monday, November 1st.

On average, analysts expect that Halozyme Therapeutics will report full-year sales of $441.58 million for the current fiscal year, with estimates ranging from $421.20 million to $461.32 million. For the next year, analysts forecast that the business will report sales of $613.90 million, with estimates ranging from $583.68 million to $683.15 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, August 9th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.19. The company had revenue of $136.50 million during the quarter, compared to the consensus estimate of $104.08 million. Halozyme Therapeutics had a return on equity of 230.77% and a net margin of 55.45%. Halozyme Therapeutics’s revenue for the quarter was up 147.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.19 EPS.

Several research firms have recently weighed in on HALO. SVB Leerink began coverage on Halozyme Therapeutics in a report on Monday, May 17th. They issued an “outperform” rating and a $56.00 target price for the company. Zacks Investment Research downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating and set a $45.00 target price for the company. in a report on Friday, July 16th. Piper Sandler restated a “neutral” rating and issued a $48.00 price target (down previously from $50.00) on shares of Halozyme Therapeutics in a research report on Monday, May 17th. Finally, Evercore ISI initiated coverage on Halozyme Therapeutics in a research report on Monday, June 14th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.67.

In related news, CEO Helen Torley sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $41.11, for a total value of $2,055,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 40,315 shares of the company’s stock in a transaction that occurred on Thursday, July 1st. The shares were sold at an average price of $45.70, for a total value of $1,842,395.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 225,315 shares of company stock worth $9,750,746. Insiders own 2.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Canada Pension Plan Investment Board acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $52,000. Assetmark Inc. increased its holdings in Halozyme Therapeutics by 32.8% in the 1st quarter. Assetmark Inc. now owns 1,235 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 305 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Halozyme Therapeutics by 67.8% in the 1st quarter. First Horizon Advisors Inc. now owns 1,403 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 567 shares in the last quarter. Lazard Asset Management LLC increased its holdings in Halozyme Therapeutics by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 2,502 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 480 shares in the last quarter. Finally, Stephens Inc. AR increased its holdings in Halozyme Therapeutics by 377.4% in the 1st quarter. Stephens Inc. AR now owns 2,530 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,000 shares in the last quarter. 89.92% of the stock is currently owned by institutional investors.

Shares of Halozyme Therapeutics stock traded up $0.42 on Tuesday, hitting $41.40. The stock had a trading volume of 714,992 shares, compared to its average volume of 1,071,711. Halozyme Therapeutics has a 52-week low of $25.17 and a 52-week high of $56.40. The company has a current ratio of 8.75, a quick ratio of 8.24 and a debt-to-equity ratio of 6.56. The stock has a market cap of $5.89 billion, a price-to-earnings ratio of 26.54 and a beta of 1.43. The company’s 50 day moving average price is $41.87 and its 200 day moving average price is $43.18.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More: What is the Euro STOXX 50 Index?

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.